Jo Shorthouse
Managing Editor, Pharma Insights
UK
15+ years of experience
In Vivo
By Jo Shorthouse 14 Nov 2022
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
Scrip
By Jo Shorthouse 02 Jul 2019
As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.
Topic Business Strategies Brexit
Scrip
By Jo Shorthouse 03 Oct 2018
Biochemist Greg Winter has scientifically contributed to some of the pharmaceutical industry's biggest commercial and therapeutic success stories. He tells Scrip how he feels about being labelled a pioneer and why he is still wary of the boardroom.
Topic Cancer
Scrip
By Jo Shorthouse 20 Sep 2018
ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.
Topic Company Analysis
Scrip
By Jo Shorthouse 06 Sep 2018
Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.
Topic Business Strategies
Scrip
By Jo Shorthouse 22 Aug 2018
Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.
Topic Clinical Trials
Scrip
By Jo Shorthouse 20 Jul 2018
Pharma has been busy making deals this year, while the political winds of change swirl overhead, as our infographic shows. Companies both big and small have been merging to carve out therapeutic niches, return value to shareholders, and position themselves for the next wave of innovation and change.
Topic Business Strategies
Scrip
By Jo Shorthouse 23 Apr 2017
This year the Scrip 100 universe is bigger than ever. We have been tunneling into the 2015 full year financial data of 620 companies to continue the Scrip 100 series, and using this data we can see even more clearly the structure of a top-heavy industry.
Scrip
By Jo Shorthouse 14 Feb 2017
Where There's A Cure There's Controversy: Raymond Schinazi's Story
Topic Research & Development
Scrip
16 May 2023
Medtech Insight
10 May 2023
In Vivo
25 Jul 2022
In Vivo
25 Jul 2022
In Vivo
04 Jul 2022
In Vivo
27 Jun 2022
Pink Sheet
11 Apr 2016
Pink Sheet
04 Apr 2016
Scrip
24 Feb 2016
Scrip
27 Jan 2016
Scrip
14 Dec 2015
Scrip
14 Dec 2015
Scrip
08 Dec 2015
Pink Sheet
30 Nov 2015
Pink Sheet
16 Oct 2015